SCHEMBL1890355

SCHEMBL1890355

Cc1cnc(NC(=O)c2c(O)c(F)c(C)n(C)c2=O)s1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
AHR P35869 1/20 0.49
SMN1; SMN2 Q16637 5/20 0.48
USP2 O75604 1/20 0.48
RAB9A P51151 9/20 0.46
NPC1 O15118 8/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
GRM5 P41594 1/20 0.45
ALDH1A1 P00352 2/20 0.45
PKM P14618 3/20 0.44
MITF O75030 1/20 0.43
POLB P06746 1/20 0.43
PTGS1 P23219 2/20 0.42
PTGS2 P35354 2/20 0.42
ABCB11 O95342 1/20 0.42
GLA P06280 1/20 0.42
EDNRA P25101 1/20 0.42
LMNA P02545 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1890247 0.79 SMN1; SMN2 (0.49) SMN1; SMN2RAB9ANPC1MEN1KMT2A
SCHEMBL1893447 0.78 AHR (0.51) AHRSMN1; SMN2USP2RAB9ANPC1
SCHEMBL1779249 0.77 NPC1 (0.46) SMN1; SMN2USP2RAB9ANPC1MEN1
SCHEMBL1399907 0.76 NPC1 (0.65) SMN1; SMN2USP2RAB9ANPC1MEN1
SCHEMBL12417647 0.73 TSHR (0.39) SMN1; SMN2RAB9ANPC1MEN1KMT2A
SCHEMBL12601083 0.73 MCHR1 (0.40) SMN1; SMN2RAB9ANPC1MEN1KMT2A
SCHEMBL12601080 0.73 RAB9A (0.47) SMN1; SMN2RAB9ANPC1MEN1KMT2A
SCHEMBL12605339 0.72 NPC1 (0.44) SMN1; SMN2USP2RAB9ANPC1MEN1
SCHEMBL1399895 0.72 KCNQ3 (0.49) SMN1; SMN2USP2RAB9ANPC1MEN1
SCHEMBL12601082 0.71 NPC1 (0.50) SMN1; SMN2USP2RAB9ANPC1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1887002-B1 CARBOXAMIDE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL CO (JP) 2015-08-26 EP disclosed
US-8304437-B2 Carboxamide compound and use of the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-11-06 US disclosed
US-8304437-B2 Carboxamide compound and use of the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-11-06 US disclosed
US-20110172276-A1 CARBOXAMIDE COMPOUND AND USE OF THE SAME ARIMORI SADAYUKI 2011-07-14 US disclosed
US-20110172276-A1 CARBOXAMIDE COMPOUND AND USE OF THE SAME ARIMORI SADAYUKI 2011-07-14 US disclosed
US-7935716-B2 Carboxamide compound and use of the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-05-03 US disclosed
US-7935716-B2 Carboxamide compound and use of the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-05-03 US disclosed
US-7935716-B2 Carboxamide compound and use of the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-05-03 US disclosed
US-20090076063-A1 Carboxamide compound and use of the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-03-19 US disclosed
US-20090076063-A1 Carboxamide compound and use of the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-03-19 US disclosed
US-20090076063-A1 Carboxamide compound and use of the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-03-19 US disclosed
EP-1887002-A1 CARBOXAMIDE COMPOUND AND USE THEREOF Sumitomo Chemical Company, Limited (JP) 2008-02-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076063-A1 Carboxamide compound and use of the same CBR3, SIRT2, SIRT1 AHR 938/4885SMN1; SMN2 2564/4885USP2 1898/4885
US-20110172276-A1 CARBOXAMIDE COMPOUND AND USE OF THE SAME CBR3, SIRT2, SIRT1 AHR 938/4885SMN1; SMN2 2564/4885USP2 1898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.